DOCETAXEL INJECTION USP 10 MG
DOCETAXEL : 10 MG · DIN 02361957 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is DOCETAXEL INJECTION USP?
DOCETAXEL INJECTION USP 10 MG contains DOCETAXEL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02361957, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOCETAXEL INJECTION USP used for?
Adjuvant node-positive breast cancer; metastatic breast cancer; non-small cell lung cancer; ovarian cancer; hormone-refractory metastatic prostate cancer; squamous cell carcinoma of head and neck.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02361957 |
|---|---|
| Brand name | DOCETAXEL INJECTION USP |
| Generic / active ingredient | DOCETAXEL : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01CD02 DOCETAXEL |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jun-2017 |
| Original market date | 2011-03-01 00:00:00 |
How is it administered?
100 mg/m2 (monotherapy) or 75 mg/m2 (combination) as a 1-hour IV infusion every 3 weeks. Premedication with oral corticosteroids is required. Dose reductions required for toxicity.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refer to section 11), but mentions allowing refrigerated vials to stand at room temperature for 5 minutes before use.
How is it supplied?
Single-dose 2 mL vial; multidose 8 mL or 16 mL vials. Vials are Type I glass with latex-free stoppers and ONCO-TAIN plastic sleeves.
Contraindications
History of hypersensitivity to docetaxel, polysorbate 80, or polyethylene glycol 300; pregnant or breastfeeding women; severe liver impairment; baseline neutrophil counts < 1,500 cells/mm3.
Warnings and precautions
Serious risks: toxic death, fatal GI hemorrhage, severe hypersensitivity, neutropenia, enterocolitis, and second primary malignancies (e.g., AML). Contains ethanol.
Is DOCETAXEL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 03 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01CD02 DOCETAXEL. 3 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOCETAXEL INJECTION | 10 MG | Injection | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02439336 |
| DOCETAXEL INJECTION | 20 MG | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | DIN 02458020 |
| ACT DOCETAXEL 40 MG/ML | 20 MG / 0.5 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | DIN 02444410 |
| ACT DOCETAXEL 40 MG/ML | 80 MG / 2 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | DIN 02441845 |
| DOCETAXEL INJECTION | 20 MG | SOLUTION | ACCORD HEALTHCARE INC | DORMANT | DIN 02437031 |
| DOCETAXEL INJECTION | 20 MG / 0.72 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02412225 |
| DOCETAXEL INJECTION | 80 MG / 2.88 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02412233 |
| PMS-DOCETAXEL | 20 MG / 0.5 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02436361 |
| PMS-DOCETAXEL | 80 MG / 2 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02436388 |
| TARO-DOCETAXEL | 160 MG / 8 ML | SOLUTION | TARO PHARMACEUTICALS INC | CANCELLED PRE MARKET | DIN 02465655 |
Who else supplies DOCETAXEL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOCETAXEL appears in 172 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.